Option Therapeutics Inc. (OPTN)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	n/a
Net Income	-1.28M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	860,961
Open	9.67
Previous Close	9.71
Day's Range	9.48 - 9.72
52-Week Range	4.82 - 20.03
Beta	-0.89
Analysts	Hold
Price Target	9.00 (-6.25%)
Earnings Date	May 14, 2025

About OPTN

Option Therapeutics is a clinical-stage company developing innovative drug therapies to treat debilitating and life-threatening liver disease through our investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 has been granted both Food and Drug Administration (“FDA”) Fast Track designation status and FDA Orphan Drug Status, which designations provide certain advantages in the review process, but do not guarantee a faster development process, regulatory review or approval as compared to the conventional FDA review and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2025
• Country: United States
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: OPTN

Analyst Summary

According to 3 analysts, the average rating for OPTN stock is "Hold." The 12-month stock price target is $9.0, which is a decrease of -6.25% from the latest price.

Price Target

$9.0

(-6.25% downside)

Analyst Consensus: Hold